content: SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
  
                                      Form 8-K
  
                  Current Report Pursuant to Section 13 or 15(d) of
                         The Securities Exchange Act of 1934
  
  
           Date of Report (Date of earliest event reported): May 24, 2002
                                                             ------------
  
  
                                 IMMUNOMEDICS, INC.
               -----------------------------------------------------
               (Exact name of registrant as specified in its charter)
  
  
  Delaware                            0-12104                    61-1009366
  --------------------------------------------------------------------------------
  (State or other                   (Commission                 (IRS Employer
  jurisdiction                     File Number)              Identification No.)
  of incorporation)
  
  
  300 American Road, Morris Plains, New Jersey                      07950
  --------------------------------------------------------------------------------
  (Address of principal executive offices)                        (Zip Code)
  
  
         Registrant's telephone number, including area code: (973) 605-8200
                                                             --------------
  
  
                                   Not applicable
  --------------------------------------------------------------------------------
            (Former name or former address, if changed since last report)
  
  
                                     Page 1 of 4
  <PAGE>
  
  
  
  ITEM 5.   OTHER EVENTS
  
  On May 24, 2002,  Immunomedics,  Inc.  announced  that it had purchased  certain
  membership interests in IBC Pharmaceuticals,  Inc. from Beckman Coulter,  Inc. A
  copy of the press release announcing this information is attached to this report
  as Exhibit 99.1 hereto and is incorporated herein by reference.
  
  
  ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
  
  
  (c)  Exhibits.
  
       99.1 Press Release issued by Immunomedics, Inc. on May 24, 2002.
  
  
                                     Page 2 of 4
  <PAGE>
  
  
  
  
                                     SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned, hereunto duly authorized.
  
  
                                       IMMUNOMEDICS, INC.
  
  
  Dated:  May 28, 2002                 By:  /s/ Cynthia L. Sullivan
                                            -----------------------
                                            Cynthia L. Sullivan
                                            President and Chief Executive Officer
  
  
                                     Page 3 of 4
  
  <PAGE>
  
                                EXHIBIT INDEX
  
  
  Exhibit No.                              Description
  -----------                              -----------
  
     99.1              Press Release issued by Immunomedics, Inc. on May 24, 2002.
  
  
                                     Page 4 of 4
  
  <PAGE>
  
                                    EXHIBIT 99.1
                                    ------------
  
  
                       IMMUNOMEDICS ACQUIRES BECKMAN COULTER'S
                            SHARE OF IBC PHARMACEUTICALS
  
  Morris  Plains,  NJ, May 24,  2002 --  Immunomedics,  Inc.  (Nasdaq:IMMU)  today
  announced that Beckman  Coulter,  Inc. sold its membership  interest in a cancer
  therapeutic joint venture, IBC Pharmaceuticals,  LLC, to Immunomedics. In return
  for its 43% interest in the joint  venture,  Beckman  Coulter  received  138,900
  shares of  Immunomedics  common  stock and a  five-year  warrant to  purchase an
  additional  150,000  shares of  Immunomedics  common stock at a price of $65 per
  share,   subject  to  adjustment  in  the  event  of  a  change  of  control  of
  Immunomedics.  Immunomedics has agreed to promptly  register with the Securities
  and Exchange  Commission all such shares for resale to the public. This transfer
  of Beckman  Coulter's  ownership of the joint venture gives  Immunomedics  a 92%
  ownership share, with other existing investors retaining an 8% ownership.
  
  Immunomedics'  President  and Chief  Executive  Officer,  Cynthia  L.  Sullivan,
  commented:  "IBC  Pharmaceuticals  focuses on the  development  of novel  cancer
  therapeutics using proprietary pre-targeting,  bi-specific antibody technologies
  developed  some years ago at  Immunotech in Marseille,  France.  Immunotech  was
  later  purchased  by Coulter  Corporation,  which  subsequently  became  part of
  Beckman Coulter.  IBC's first product  candidate is currently being evaluated in
  Phase  I/II  clinical  trials  in France  for the  therapy  of tumors  producing
  carcinoembryonic antigen, or CEA."
  
  "IBC  Pharmaceuticals  and  Immunomedics   scientists  have  been  reengineering
  bi-specific,  fused  antibodies  against CEA and a second  carrier  peptide that
  delivers  therapeutic  doses of  radiation  to cancer  cells at ratios to normal
  tissues that appear to exceed those of directly-radiolabeled  antibodies.  Since
  we are a leader in the use of  radiolabeled  antibodies for cancer  therapy,  we
  were  delighted  to be able to increase our  ownership in the joint  venture and
  believe this will help us accelerate the  development of this  technology,"  Ms.
  Sullivan remarked.
  
  IBC Pharmaceuticals  currently has a 5-person  management board,  chaired by Dr.
  David M. Goldenberg,  who is also the Chairman and Chief  Scientific  Officer of
  Immunomedics,  Inc. Dr. Goldenberg stated: "I am grateful to Beckman Coulter for
  the assistance and advice  provided  during the formative years of this venture,
  which is now entering a second stage of development. I am also pleased that they
  have decided to become shareholders of Immunomedics."
  
  Immunomedics  is  a  biopharmaceutical   company  focused  on  the  development,
  manufacture and commercialization of diagnostic imaging and therapeutic products
  for the detection and treatment of cancer and infectious  diseases.  Integral to
  these products are highly specific monoclonal  antibodies and antibody fragments
  designed  to deliver  radioisotopes  and  chemotherapeutic  agents to tumors and
  sites of  infection.  Immunomedics  has five  therapeutic  products  in clinical
  trials and has two  marketed  diagnostic  imaging  products.  The most  advanced
  therapeutic  product  candidates are LymphoCide(TM)  (epratuzumab),  which is in
  Phase II and  Phase III  clinical  trials  for the  treatment  of  non-Hodgkin's
  lymphoma, and CEA-Cide(TM) (labetuzumab), which is in Phase I/II clinical trials
  for the treatment of certain solid tumors.
  
  This release, in addition to historical  information,  contains  forward-looking
  statements  made  pursuant to the Private  Securities  Litigation  Reform Act of
  1995. Such statements,  including statements regarding clinical trials,  involve
  significant  risks and  uncertainties and actual results could differ materially
  from  those  expressed  or  implied  herein.   Factors  that  could  cause  such
  differences  include,  but are not limited to, risks associated with new product
  development     (including    clinical    trials    outcome    and    regulatory
  requirements/actions),  competitive  risks to marketed products and availability
  of financing and other sources of capital, as well as the risks discussed in the
  Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2002.
  
  Company Contact: Rebecca Kinner, Investor Relations,  (973) 605-8200,  extension
  263. Visit the company's web site at http://www.Immunomedics.com
  
  
                                     Page 1 of 1
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "may8k2002.txt", "description": "IBC PHARMACEUTICALS", "secsgml_size_bytes": 7624}]
metadata_filer: {"company-data": {"conformed-name": "IMMUNOMEDICS INC", "cik": "0000722830", "assigned-sic": "2835", "irs-number": "611009366", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12104", "film-number": "02663050"}, "business-address": {"street1": "300 AMERICAN RD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950", "phone": "9736058200"}, "mail-address": {"street1": "300 AMERICAN ROAD", "city": "MORRIS PLAINS", "state": "NJ", "zip": "07950"}}
text: SECURITIES AND EXCHANGE COMMISSION
                               Washington, D.C. 20549
  
                                      Form 8-K
  
                  Current Report Pursuant to Section 13 or 15(d) of
                         The Securities Exchange Act of 1934
  
           Date of Report (Date of earliest event reported): May 24, 2002
                                                             ------------
  
                                 IMMUNOMEDICS, INC.
               -----------------------------------------------------
               (Exact name of registrant as specified in its charter)
  
  Delaware                            0-12104                    61-1009366
  --------------------------------------------------------------------------------
  (State or other                   (Commission                 (IRS Employer
  jurisdiction                     File Number)              Identification No.)
  of incorporation)
  
  300 American Road, Morris Plains, New Jersey                      07950
  --------------------------------------------------------------------------------
  (Address of principal executive offices)                        (Zip Code)
  
         Registrant's telephone number, including area code: (973) 605-8200
                                                             --------------
  
                                   Not applicable
  --------------------------------------------------------------------------------
            (Former name or former address, if changed since last report)
  
                                     Page 1 of 4
  ITEM 5.   OTHER EVENTS
  
  On May 24, 2002,  Immunomedics,  Inc.  announced  that it had purchased  certain
  membership interests in IBC Pharmaceuticals,  Inc. from Beckman Coulter,  Inc. A
  copy of the press release announcing this information is attached to this report
  as Exhibit 99.1 hereto and is incorporated herein by reference.
  
  ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
  
  (c)  Exhibits.
  
       99.1 Press Release issued by Immunomedics, Inc. on May 24, 2002.
  
                                     Page 2 of 4
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned, hereunto duly authorized.
  
                                       IMMUNOMEDICS, INC.
  
  Dated:  May 28, 2002                 By:  /s/ Cynthia L. Sullivan
                                            -----------------------
                                            Cynthia L. Sullivan
                                            President and Chief Executive Officer
  
                                     Page 3 of 4
  EXHIBIT INDEX
  
  Exhibit No.                              Description
  -----------                              -----------
  
     99.1              Press Release issued by Immunomedics, Inc. on May 24, 2002.
  
                                     Page 4 of 4
  EXHIBIT 99.1
                                    ------------
  
                       IMMUNOMEDICS ACQUIRES BECKMAN COULTER'S
                            SHARE OF IBC PHARMACEUTICALS
  
  Morris  Plains,  NJ, May 24,  2002 --  Immunomedics,  Inc.  (Nasdaq:IMMU)  today
  announced that Beckman  Coulter,  Inc. sold its membership  interest in a cancer
  therapeutic joint venture, IBC Pharmaceuticals,  LLC, to Immunomedics. In return
  for its 43% interest in the joint  venture,  Beckman  Coulter  received  138,900
  shares of  Immunomedics  common  stock and a  five-year  warrant to  purchase an
  additional  150,000  shares of  Immunomedics  common stock at a price of $65 per
  share,   subject  to  adjustment  in  the  event  of  a  change  of  control  of
  Immunomedics.  Immunomedics has agreed to promptly  register with the Securities
  and Exchange  Commission all such shares for resale to the public. This transfer
  of Beckman  Coulter's  ownership of the joint venture gives  Immunomedics  a 92%
  ownership share, with other existing investors retaining an 8% ownership.
  
  Immunomedics'  President  and Chief  Executive  Officer,  Cynthia  L.  Sullivan,
  commented:  "IBC  Pharmaceuticals  focuses on the  development  of novel  cancer
  therapeutics using proprietary pre-targeting,  bi-specific antibody technologies
  developed  some years ago at  Immunotech in Marseille,  France.  Immunotech  was
  later  purchased  by Coulter  Corporation,  which  subsequently  became  part of
  Beckman Coulter.  IBC's first product  candidate is currently being evaluated in
  Phase  I/II  clinical  trials  in France  for the  therapy  of tumors  producing
  carcinoembryonic antigen, or CEA."
  
  "IBC  Pharmaceuticals  and  Immunomedics   scientists  have  been  reengineering
  bi-specific,  fused  antibodies  against CEA and a second  carrier  peptide that
  delivers  therapeutic  doses of  radiation  to cancer  cells at ratios to normal
  tissues that appear to exceed those of directly-radiolabeled  antibodies.  Since
  we are a leader in the use of  radiolabeled  antibodies for cancer  therapy,  we
  were  delighted  to be able to increase our  ownership in the joint  venture and
  believe this will help us accelerate the  development of this  technology,"  Ms.
  Sullivan remarked.
  
  IBC Pharmaceuticals  currently has a 5-person  management board,  chaired by Dr.
  David M. Goldenberg,  who is also the Chairman and Chief  Scientific  Officer of
  Immunomedics,  Inc. Dr. Goldenberg stated: "I am grateful to Beckman Coulter for
  the assistance and advice  provided  during the formative years of this venture,
  which is now entering a second stage of development. I am also pleased that they
  have decided to become shareholders of Immunomedics."
  
  Immunomedics  is  a  biopharmaceutical   company  focused  on  the  development,
  manufacture and commercialization of diagnostic imaging and therapeutic products
  for the detection and treatment of cancer and infectious  diseases.  Integral to
  these products are highly specific monoclonal  antibodies and antibody fragments
  designed  to deliver  radioisotopes  and  chemotherapeutic  agents to tumors and
  sites of  infection.  Immunomedics  has five  therapeutic  products  in clinical
  trials and has two  marketed  diagnostic  imaging  products.  The most  advanced
  therapeutic  product  candidates are LymphoCide(TM)  (epratuzumab),  which is in
  Phase II and  Phase III  clinical  trials  for the  treatment  of  non-Hodgkin's
  lymphoma, and CEA-Cide(TM) (labetuzumab), which is in Phase I/II clinical trials
  for the treatment of certain solid tumors.
  
  This release, in addition to historical  information,  contains  forward-looking
  statements  made  pursuant to the Private  Securities  Litigation  Reform Act of
  1995. Such statements,  including statements regarding clinical trials,  involve
  significant  risks and  uncertainties and actual results could differ materially
  from  those  expressed  or  implied  herein.   Factors  that  could  cause  such
  differences  include,  but are not limited to, risks associated with new product
  development     (including    clinical    trials    outcome    and    regulatory
  requirements/actions),  competitive  risks to marketed products and availability
  of financing and other sources of capital, as well as the risks discussed in the
  Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2002.
  
  Company Contact: Rebecca Kinner, Investor Relations,  (973) 605-8200,  extension
  263. Visit the company's web site at http://www.Immunomedics.com
  
                                     Page 1 of 1